Literature DB >> 3221261

Intra-arterial 5-bromo-2-deoxyuridine (BUdR) radiosensitization with external beam radiation in rhesus monkeys: toxicity study.

H S Greenberg1, W F Chandler, R F Diaz, D R Averill, S S Gebarski, A S Lichter, W D Ensminger.   

Abstract

A primate toxicity study was performed to test the hypothesis that BUdR does not increase the likelihood of unilateral or bilateral central nervous system damage secondary to radiation therapy. BUdR, a halogenated pyrimidine analog is incorporated into DNA of dividing cells and sensitizes them to radiation. It is best given unilaterally, intra-arterially by continuous infusion because of its regional advantage (Rd) estimated to be between 11 and 16. Six rhesus monkeys were implanted with a Model 400 Infusaid pump perfusing the right internal carotid artery. Three of the six monkeys received intra-arterial (IA) BUdR infusion plus whole brain external beam radiation (6,000 R over 6 weeks) and three received radiation alone. The two BUdR treated animals completing radiation developed symmetric bilateral high signal aberrations on MRI in the frontal, parietal, and occipital centrum semiovale and corona radiata at nine months. At autopsy, confluent microinfarcts were found to correspond topographically to the MRI abnormalities. In the radiation alone group, two animals had normal MRI and autopsy while the third animal had bilateral MRI high signal aberrations develop sequentially with corresponding microinfarcts at autopsy. These changes were greater in severity than those seen in the BUdR treated animals. We support previous evidence that there is differential intraspecies sensitivity to radiation. We find that BUdR produces no unilateral potentiation of radiation toxicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3221261     DOI: 10.1007/bf00177431

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  9 in total

1.  An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.

Authors:  M D Walker; T A Strike; G E Sheline
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-10       Impact factor: 7.038

2.  New implantable continuous administration and bolus dose intracarotid drug delivery system for the treatment of malignant gliomas.

Authors:  T W Phillips; W F Chandler; G W Kindt; W D Ensminger; H S Greenberg; J F Seeger; K M Doan; J W Gyves
Journal:  Neurosurgery       Date:  1982-08       Impact factor: 4.654

3.  Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors.

Authors:  A Russo; L Gianni; T J Kinsella; R W Klecker; J Jenkins; J Rowland; E Glatstein; J B Mitchell; J Collins; C Myers
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

4.  A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation.

Authors:  T J Kinsella; A Russo; J B Mitchell; J Rowland; J Jenkins; J Schwade; C E Myers; J M Collins; J Speyer; P Kornblith
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-01       Impact factor: 7.038

5.  S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine.

Authors:  T Hoshino; T Nagashima; K G Cho; J A Murovic; J E Hodes; C B Wilson; M S Edwards; L H Pitts
Journal:  Int J Cancer       Date:  1986-09-15       Impact factor: 7.396

6.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.

Authors:  M D Walker; E Alexander; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; H A Norrell; G Owens; J Ransohoff; C B Wilson; E A Gehan; T A Strike
Journal:  J Neurosurg       Date:  1978-09       Impact factor: 5.115

7.  Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer.

Authors:  T J Kinsella; J B Mitchell; A Russo; M Aiken; G Morstyn; S M Hsu; J Rowland; E Glatstein
Journal:  J Clin Oncol       Date:  1984-10       Impact factor: 44.544

8.  Acute cerebral infarction in monkeys: an experimental study using MR imaging.

Authors:  E C Unger; M H Gado; K F Fulling; J L Littlefield
Journal:  Radiology       Date:  1987-03       Impact factor: 11.105

9.  Genetics of human cell lines. III. Incorporation of 5-bromo- and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity.

Authors:  B DJORDJEVIC; W SZYBALSKI
Journal:  J Exp Med       Date:  1960-09-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.